Huang FL, Liao EC, Li CL, et al. Pathogenesis of pediatric B-cell acute lymphoblastic leukemia: molecular pathways and disease treatments. Oncol Lett. 2020;20(1):448–54.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Jasinski S, De Los Reyes FA, Yametti GC, et al. Immunotherapy in pediatric B-cell acute lymphoblastic leukemia: advances and ongoing challenges. Paediatr Drugs. 2020;22(5):485–99.

Article  PubMed  PubMed Central  Google Scholar 

DiJoseph JF, Armellino DC, Boghaert ER, et al. Antibody-targeted chemotherapy with CMC-544: a CD22-targeted immunoconjugate of calicheamicin for the treatment of B-lymphoid malignancies. Blood. 2004;103(5):1807–14.

Article  CAS  PubMed  Google Scholar 

Xu J, Luo W, Li C, et al. Targeting CD22 for B-cell hematologic malignancies. Exp Hematol Oncol. 2023;12(1):90.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Shah NN, Stevenson MS, Yuan CM, et al. Characterization of CD22 expression in acute lymphoblastic leukemia. Pediatr Blood Cancer. 2015;62(6):964–9.

Article  CAS  PubMed  PubMed Central  Google Scholar 

US Food & Drug Administration. FDA approves inotuzumab ozogamicin for pediatric patients with acute lymphoblastic leukemia [media release]. 6 Mar 2024. https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-inotuzumab-ozogamicin-pediatric-patients-acute-lymphoblastic-leukemia.

Pfizer Limited. BESPONSA (inotuzumab ozogamicin): US prescribing information. 2023. https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/761040s003lbl.pdf. Accessed 2 Apr 2024.

Pfizer. Besponsa® for intravenous infusion receives approval for dosage and administration for children with relapsed or refractory CD22-positive acute lymphoblastic leukemia [media release]. 26 Mar 2024. https://www.pfizer.co.jp/pfizer/company/press/2024/2024-03-26-05.

Celltech Group PLC. Annual report, 2003. 2003. https://www.sec.gov/Archives/edgar/data/877799/000119312504108577/d20f.htm. Accessed 27 Mar 2024.

Pfizer. Pfizer Receives U.S. FDA Approval for BESPONSA® (inotuzumab ozogamicin) [media release]. 17 Aug 2017. https://www.pfizer.com/news/press-release/press-release-detail/pfizer_receives_u_s_fda_approval_for_besponsa_inotuzumab_ozogamicin.

de Vries JF, Zwaan CM, De Bie M, et al. The novel calicheamicin-conjugated CD22 antibody inotuzumab ozogamicin (CMC-544) effectively kills primary pediatric acute lymphoblastic leukemia cells. Leukemia. 2012;26(2):255–64.

Article  PubMed  Google Scholar 

DiJoseph JF, Dougher MM, Armellino DC, et al. Therapeutic potential of CD22-specific antibody-targeted chemotherapy using inotuzumab ozogamicin (CMC-544) for the treatment of acute lymphoblastic leukemia. Leukemia. 2007;21(11):2240–5.

Article  CAS  PubMed  Google Scholar 

Pennesi E, Brivio E, Pelletier KB, et al. Population pharmacokinetics of inotuzumab ozogamicin (InO) as single agent in pediatric relapsed/refractory acute lymphoblastic leukemia: results from the ITCC-059 phase IA and phase II trial [abstract no. 3987]. Blood. 2022;140(Suppl 1):8845–7.

Article  Google Scholar 

Brivio E, Locatelli F, Lopez-Yurda M, et al. A phase 1 study of inotuzumab ozogamicin in pediatric relapsed/refractory acute lymphoblastic leukemia (ITCC-059 study). Blood. 2021;137(12):1582–90.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Pennesi E, Michels N, Brivio E, et al. Inotuzumab ozogamicin as single agent in pediatric patients with relapsed and refractory acute lymphoblastic leukemia: results from a phase II trial. Leukemia. 2022;36(6):1516–24.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Pennesi E, Brivio E, Ammerlaan ACJ, et al. Inotuzumab ozogamicin combined with chemotherapy in pediatric B-cell precursor CD22+ acute lymphoblastic leukemia: results of the phase IB ITCC-059 trial. Haematologica. 2024. https://doi.org/10.3324/haematol.2023.284409.

Article  PubMed  Google Scholar 

O’Brien MM, Ji L, Shah NN, et al. Phase II trial of inotuzumab ozogamicin in children and adolescents with relapsed or refractory B-cell acute lymphoblastic leukemia: Children’s Oncology Group Protocol AALL1621. J Clin Oncol. 2022;40(9):956–67.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Calvo C, Cabannes-Hamy A, Adjaoud D, et al. Inotuzumab ozogamicin compassionate use for French paediatric patients with relapsed or refractory CD22-positive B-cell acute lymphoblastic leukaemia. Br J Haematol. 2020;190(1):e53–6.

Article  CAS  PubMed  Google Scholar 

Bhojwani D, Sposto R, Shah NN, et al. Inotuzumab ozogamicin in pediatric patients with relapsed/refractory acute lymphoblastic leukemia. Leukemia. 2019;33(4):884–92.

Article  CAS  PubMed  Google Scholar 

Evstratov DA, Shutova AD, Dyakonova YY, et al. The use of inotuzumab ozogamicin in children with relapsed/refractory B-lineage acute lymphoblastic leukemia. Pediatr Hematol Oncol Immunopathol. 2023;22(1):46–52.

Article  Google Scholar 

Rytting M, Triche L, Thomas D, et al. Initial experience with CMC-544 (inotuzumab ozogamicin) in pediatric patients with relapsed B-cell acute lymphoblastic leukemia. Pediatr Blood Cancer. 2014;61(2):369–72.

Article  PubMed  Google Scholar